This Diabetes Company's Q1 Earnings Reflect the Resiliency of Its Business Model

Insulet (NASDAQ:PODD) earlier this month reported first-quarter 2020 results. The tubeless insulin pump specialist's results were quite strong, especially in light of the COVID-19 pandemic.

In 2020, shares of the healthcare company are up 10.2% through the end of May, outpacing the broader market, which is down about 5% because of the pandemic. Insulet stock remains a huge winner over the intermediate and long terms. Over the past five years, it's gained 567%, versus the broader market's 60% return.